• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Global regenerative medicine market poised for strong growth

Report: Global regenerative medicine market poised for strong growth

July 21, 2016
CenterWatch Staff

A strong development pipeline for regenerative medicine (RM) therapies aimed at treating a broad range of unmet medical needs signals rapid growth in global RM product sales that could have significant and positive impacts on public health, according to a newly completed analysis by the Tufts Center for the Study of Drug Development.

Today, there are 640  privately held and  publicly traded companies  in Europe, Japan, and the U.S. that are actively engaged in developing RM therapies, said Christopher-Paul Milne, research associate professor and director of research at Tufts CSDD at Tufts University School of Medicine, who conducted the analysis.

RM therapies boost the body’s natural ability to heal itself, use healthy cells, tissues, or organs from a living or deceased donor to replace damaged ones, or deliver specific types of cells or cell products to diseased tissues or organs to restore tissue and organ function.

Milne noted that RM-enabling technologies—traditionally based on research in transplantation science, biomechanics, stem cell biology, molecular biology, vector engineering, advanced materials, immunology and recombinant DNA technology—have taken a quantum leap forward with the introduction of cell- and gene-based therapies and tissue engineering.

Despite strong prospects for RM therapies, developers face "substantial challenges," not least of which are uncertain reimbursement prospects, according to Milne.

"Payers in the U.S. and elsewhere increasingly are applying strict cost-benefit analyses to a growing number of medicines to guide reimbursement policy, which means developers will have to show that the benefits of RM products justify their cost," Milne said.

Key findings from the analysis, reported in the July/August Tufts CSDD Impact Report, released today, include the following:

  • Cell therapy products account for 76% of the 915 RM products currently in development in Europe, Japan and the U.S., with gene therapy products accounting for the balance.
  • The Japan and Asia-Pacific region is the fastest growing market for RM therapies through 2020.
  • While regulators in Europe and Japan have put in place specific pathways for RM product development, the FDA does not plan to do so, but Congress is considering such a bill.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing